GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » EV-to-FCF

Alliance Pharma (LSE:APH) EV-to-FCF : 9.96 (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alliance Pharma's Enterprise Value is £287.2 Mil. Alliance Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £28.8 Mil. Therefore, Alliance Pharma's EV-to-FCF for today is 9.96.

The historical rank and industry rank for Alliance Pharma's EV-to-FCF or its related term are showing as below:

LSE:APH' s EV-to-FCF Range Over the Past 10 Years
Min: -1086.34   Med: 17.86   Max: 30.73
Current: 9.96

During the past 13 years, the highest EV-to-FCF of Alliance Pharma was 30.73. The lowest was -1086.34. And the median was 17.86.

LSE:APH's EV-to-FCF is ranked better than
78.63% of 510 companies
in the Drug Manufacturers industry
Industry Median: 22.655 vs LSE:APH: 9.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Alliance Pharma's stock price is £0.3495. Alliance Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.014. Therefore, Alliance Pharma's PE Ratio for today is At Loss.


Alliance Pharma EV-to-FCF Historical Data

The historical data trend for Alliance Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma EV-to-FCF Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.64 16.06 15.69 20.39 19.25

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 20.39 - 19.25 -

Competitive Comparison of Alliance Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's EV-to-FCF falls into.



Alliance Pharma EV-to-FCF Calculation

Alliance Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=287.184/28.829
=9.96

Alliance Pharma's current Enterprise Value is £287.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £28.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (LSE:APH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alliance Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3495/-0.014
=At Loss

Alliance Pharma's share price for today is £0.3495.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alliance Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q4 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024